A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML [acute myeloid leukaemia] or Intermediate-2 or High-Risk MDS

Trial Profile

A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML [acute myeloid leukaemia] or Intermediate-2 or High-Risk MDS

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Azacitidine (Primary) ; Mocetinostat (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors MethylGene; Mirati Therapeutics
  • Most Recent Events

    • 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center).
    • 13 May 2009 Actual patient number (6) added as reported by ClinicalTrials.gov
    • 23 Jul 2008 Status changed from recruiting to in progress, as reported on clinicaltrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top